1 results match your criteria: "Department of Oncology and Chemoradiotherapy of Rui'an People Hospital[Affiliation]"
Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer.
Asian Pac J Cancer Prev
February 2014
Department of Oncology and Chemoradiotherapy of Rui'an People Hospital, Wenzhou, Zhejiang, China.
Aim: To investigate the effectiveness and adverse effects of gemcitabine by fixed-dose rate infusion plus oxaliplatin (GEMOX regimen) as second-line therapy for advanced ovarian cancer.
Methods: 64 patients with advanced ovarian cancer were divided into an experimental group (44 cases) and a control group (20 cases). The experimental group was treated with continuous intravenous infusion of gemcitabine at 1000 mg/m(2) with a fixed-dose rate of 10 mg/m(2)/min, on days 1 and 8 and oxaliplatin at 100 mg/m(2) on day 1, IVGTT, repeated every 3 weeks.